Metastatic pancreatic cancer: a new standardised dose-reduction regimen?
- PMID: 39159647
- DOI: 10.1016/S2468-1253(24)00227-9
Metastatic pancreatic cancer: a new standardised dose-reduction regimen?
Conflict of interest statement
PG reports grant funding to her institution from Cancer Research UK; she is a member of the data monitoring committee for the TATRA trial. DP reports grant funding to his institution from BMS and consulting fees from BMS and Celgene.
Comment on
-
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16. Lancet Gastroenterol Hepatol. 2024. PMID: 39159648 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical